Is Exenatide Improving the Treatment of Type 2 Diabetes? Analysis of the Individual Clinical Trials with Exenatide

E-ISSN： 1876-1038|2|1|77-84

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.2, Iss.1, 2007-01, pp. : 77-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

By Ray Joshua A. Boye Kristina S. Yurgin Nicole Valentine William J. Roze Stéphane McKendrick Jan Tucker Daniel M. D. Foos Volker Palmer Andrew J.

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 609-622

Informa Healthcare

Access to resources Recommend Favorite

Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting

By Bergenstal Richard M. Garrison Louis P. Wintle Matthew Blickensderfer Amy Wade Rolin Hou Likun Miller Lesley-Ann Scism-Bacon Jamie Zagar Anthony Misurski Derek Herman William H.

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 531-540

Informa Healthcare

Access to resources Recommend Favorite

Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

By Bergenstal Richard M. Garrison Louis P. Miller Lesley-Ann Hou Likun Blickensderfer Amy Zagar Anthony Stanley Shelley Bhargava Anuj Wade Rolin Herman William H.

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2335-2342

Informa Healthcare

Access to resources Recommend Favorite

Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide

By Schwartz Stanley

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3009-3022

Informa Healthcare

Access to resources Recommend Favorite